| Document |
Document Title |
|
WO/2024/057249A1 |
The present invention relates to an improved process for the preparation of sulfonylurea based compounds of general formula (I). More specifically present invention provides an improved process for the preparation of compound of formula ...
|
|
WO/2024/059821A2 |
Compositions for the treatment of cancer that include CAR T cells in which expression of FOXO3 expression is silenced are disclosed in various aspects. In various other aspects, methods for preventing or delaying a development of dysfunc...
|
|
WO/2024/059333A1 |
This disclosure describes compounds of Formula I and Formula II, pharmaceutically acceptable salts or derivatives thereof, and pharmaceutical compositions thereof, useful in treating infections caused by parasitic protozoa, in particular...
|
|
WO/2024/055272A1 |
Provided is an mRNA expression vector capable of efficiently expressing a target protein, the mRNA expression vector, sequentially from the 5' end to the 3' end, comprising: (a) a 5'-UTR element; (b) an open reading frame element encodin...
|
|
WO/2023/159307A9 |
Disclosed are compounds and pharmaceutically acceptable salts of formula (I), which feature either a N-(1H-pyrazol-3-yl)pyridin-2-amine or a N-(1H-pyrazol-3-yl)pyrimidin-4-amine core structure. These compounds may be used in the treatmen...
|
|
WO/2024/056074A1 |
The present disclosure relates to a combination of an FAK inhibitor, a topoisomerase inhibitor, and an immune checkpoint inhibitor for use in treating a tumor. The present disclosure also relates to a combination of an FAK inhibitor and ...
|
|
WO/2023/081299A9 |
The present disclosure provides a method for noninvasively diagnosing and staging a progressive chronic lung disease characterized by disease related lung dysfunction by deriving from a biological sample from a subject a purified enriche...
|
|
WO/2024/058099A1 |
The present disclosure provides granules for suspension. Specifically, the present disclosure is a pharmaceutical composition comprising: a compound represented by formula 1 or a pharmaceutically acceptable salt or solvate thereof; a bin...
|
|
WO/2024/059881A2 |
Nucleic acid products are provided that modulate, in particular interfere with or inhibit AGT gene expression. The products can be oligomeric compounds that comprise at least a first region of linked nucleosides having at least a first n...
|
|
WO/2024/059661A1 |
Provided herein are compounds of formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, R1, R2, R3, R4, Y1, Y2, X1, X2, L, and Q1 are as defined elsewhere herein. A...
|
|
WO/2024/059806A1 |
The disclosure is directed to compounds of Formula (I). Pharmaceutical compositions comprising compounds of Formula (I), as well as methods of their use and preparation, are also described.
|
|
WO/2024/059205A1 |
Disclosed are compounds, compositions, and methods useful for treating or preventing a disease or disorder associated with abnormal levels of amino acids by modulation of SLC6A19 transport.
|
|
WO/2024/059200A1 |
Compounds having activity as inhibitors of NEK7 are provided. The compounds have Structure (I): (I) or a stereoisomer, tautomer, or salt thereof, wherein A, W, X, Y, Z, R1, and R2 are as defined herein. Methods associated with preparatio...
|
|
WO/2024/059241A1 |
The present invention relates to high concentration ophthalmic pharmaceutical formulations of the phosphodiesterase-4 inhibitor, roflumilast, which are suitable for intravitreal or other ocular administration to injection sites internal ...
|
|
WO/2024/058551A1 |
The present invention relates to: a pharmaceutical composition for the prevention or treatment of liver cancer, comprising cannabidiol (CBD) and an anticancer agent as active ingredients; and use thereof. The composition of the present i...
|
|
WO/2024/058065A1 |
A drug delivery composition comprising: a first particle that includes a first temperature responsive macromolecule and a first macromolecule having a first reactive functional group; and a second particle that includes a second temperat...
|
|
WO/2024/056798A1 |
The present invention relates to macrocyclic compounds of Formula (I) wherein Ar1, Ar2, R1, R2, R3, R4, and X are as described in the description, their preparation, to pharmaceutically 5 acceptable salts thereof, and to their use as pha...
|
|
WO/2024/059717A1 |
Methods for treating a neuropsychiatric disorder by administering an iboga alkaloid and a cardioprotective agent in conjunction with analysis of brain image data is described. Also described are methods to improve brain health and to slo...
|
|
WO/2024/059174A1 |
This document relates to methods and materials for treating cancer. For example, this document provides vesicles (e.g., nanovesicles) designed to deliver one or more (e.g., one, two, three, or more) inhibitors to a cancer cell within a m...
|
|
WO/2024/059664A2 |
This invention relates to Compound 1 (APX3330) salts and esters. The invention also provides compositions comprising a Compound 1 salt or ester. The invention also provides compounds of formula (I) and formula (II) and pharmaceutically a...
|
|
WO/2024/059781A1 |
Described are 6-aryl isoindolin-1-ones as negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating ...
|
|
WO/2024/056749A1 |
The present disclosure relates to a pharmaceutical injectable solution comprising dopamine or a pharmaceutically acceptable salt thereof, preferably dopamine hydrochloride, dissolved in water for injection, wherein the solution has a pH ...
|
|
WO/2024/059163A1 |
The present invention relates to highly pure and crystalline compounds as starting materials and intermediates to make maralixibat and the processes of making highly pure maralixibat. The invention also relates to an amorphous form of ma...
|
|
WO/2024/056498A1 |
The present invention relates to a compound having general Formula (I), (I), (e.g., oxindole alkaloid or its derivatives; (e.g., rotundifoline and rhynchophylline (compounds 1 and 2) or their derivatives or analogues thereof) for use as ...
|
|
WO/2024/059735A2 |
Provided are recombinant adeno-associated virus (rAAV) vectors, methods of treating an ocular condition, pharmaceutical compositions, and other compositions and methods, in which the rAAV vector comprises a polynucleotide encoding oxidor...
|
|
WO/2024/059713A2 |
Compositions comprising an iboga alkaloid and a cardioprotective agent are provided. Use of the compositions in treating neuropsychiatric disorders are described, where the cardioprotective agent is administered before, during and/or aft...
|
|
WO/2024/056659A1 |
The present invention relates to the treatment of cancer. Here, the inventors identified a subset of prostate cancer patients showing an up-regulation of the epigenetic enzymes SUV4-20H1 and SUV4-20H2, two methyltransferases responsible ...
|
|
WO/2024/056063A1 |
The present application belongs to the field of pharmaceuticals, and relates to a series of compounds containing hexahydro-spiro[cyclopropane-1,2'-pyrrolizine], and particularly, to a compound represented by formula (III), a stereoisomer...
|
|
WO/2024/057020A1 |
This invention relates to compounds that can be used to treat viral infections. The compounds are papain-like protease (PLpro) inhibitors.
|
|
WO/2024/058984A2 |
Methods and uses of compositions (e.g. comprising one or more microbial strains, one or more components, one or more metabolites, or a combination thereof) for treating insulin-associated diseases, disorders, and conditions are disclosed.
|
|
WO/2024/058276A1 |
Provided is an agent for improving the composite memory of a normal person, which contains uridylic acid as an active ingredient.
|
|
WO/2024/058762A1 |
The present invention relates to the cytotoxic activity and tyrosine kinase inhibitory effects of 1-benzyl-3-(1H-indol-3-ylmethylidene)-1,3-dihydro-2H-indol-2
-one derivatives. The invention provides novel 1-benzyl-3-(1H-indol-3-ylmethyl...
|
|
WO/2024/058812A1 |
The embodiments of the present invention relate to a stable liquid vigabatrin pharmaceutical compositions in the liquid form of a solution. Particularly, the stable vigabatrin liquid pharmaceutical composition is manufactured as a ready-...
|
|
WO/2024/059665A1 |
Provided herein are compounds of formula (I): (G1-Z1)-L-(G2-Z2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein G1, G2, Z1, Z2, and L, are as defined elsewhere herein. Also p...
|
|
WO/2024/059630A2 |
The present disclosure relates to a method for treating cancer in a subject that is BRCA-negative and homologous repair proficient (HRP), the method comprising administering to the subject a nucleic acid vector (e.g., a plasmid) comprisi...
|
|
WO/2024/057288A1 |
Methods are provided for treating acne vulgaris in subjects having acne vulgaris and oily skin and for treating truncal acne. Compositions comprising tazarotene or a pharmaceutically acceptable salt of tazarotenic acid in an oily-in-wate...
|
|
WO/2024/059005A1 |
Disclosed are compounds, compositions, and methods useful for treating or preventing a disease or disorder associated with abnormal levels of amino acids by modulation of SLC6A19 transport.
|
|
WO/2024/059056A1 |
This disclosure relates to methods of treating or preventing traumatic brain injury (TBI) or related conditions comprising administering an effective amount of poly [4-styrenesulfonic acid-co-maleic acid] (PSCMA) or alternative anionic p...
|
|
WO/2024/059236A1 |
The invention provides novel camptothecin analogs and immunoconjugates thereof, as well as pharmaceutical compositions and methods of preparation and use for treating various diseases and disorders (e.g., cancer).
|
|
WO/2024/059558A1 |
The present disclosure relates generally to compounds of Formulae (l-A), (l-B1), (l-C) and ((l-D) and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, method...
|
|
WO/2024/056865A1 |
The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the ClC...
|
|
WO/2024/055992A1 |
The present disclosure relates to a tricyclic compound represented by formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and use thereof in preventing or treating a PI3Kα-related disease.
|
|
WO/2024/057338A1 |
The present disclosure provides a method for expressing miR-449a in a neuronal cell by administering a viral vector comprising a nucleotide sequence containing a miRNA-449a sequence. The present disclosure also provides a method for trea...
|
|
WO/2024/059607A1 |
The present disclosure relates to physical forms of a PRC2 inhibitor compound, pharmaceutical compositions comprising the physical forms of the compound, and methods of treating subjects having cancer by administering the physical forms,...
|
|
WO/2024/056782A1 |
The application relates to sulfone-substituted pyrido[3,4-d]pyrimidine compounds of general formula (I), to pharmaceutical compositions and combinations comprising them and their medical use for the treatment or prophylaxis of hyperproli...
|
|
WO/2024/056791A1 |
The present invention concerns the compounds of formula (I) wherein R1, R2, R3, R4, X, Ar1 and Ar2 are as described in the description, and their use in the treatment of CFTR- related diseases and disorders, especially in the treatment o...
|
|
WO/2024/059309A1 |
In one aspect, a block copolymer described herein comprises a hydrophilic block including oxazoline monomer or oxazine monomer, and a cationic block comprising monomer including a linear or branched polyamine side chain. In another aspec...
|
|
WO/2024/056858A1 |
A compound of formula (I) wherein n is 0 to 4; m is 0 or 1 with the proviso that the sulphur atom and R3 are in vicinal position (if m = 0 then R3 is in position 2´, and if m = 1 then R3 is on position 1´); R is ethyl or vinyl; R1 is h...
|
|
WO/2024/058093A1 |
According to the present invention, granules are prepared by combining a core containing an active ingredient with a coating layer coating the core. The granules can control the elution speed and lag time of the active ingredient accordi...
|
|
WO/2024/058651A1 |
The present invention relates to the field of medicinal chemistry, with emphasis on the therapeutic effects of combining antioxidant and anticarcinogenic compounds, wherein the cytotoxic and antitumour properties of argentatins are combi...
|
